Compare Adobe Systems Inc (ADBE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Neurocrine Biosciences Inc — how do they compare? Adobe Systems Inc trades at $220.65 (market cap $88.06B), while Neurocrine Biosciences Inc trades at $176.78 (market cap $17.84B). The key difference: Adobe Systems Inc is far larger — about 4.9× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | NBIX | |
|---|---|---|
Market Cap | $88.06B | $17.84B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $177.49 |
52-Week Low | $193.41 | $123.10 |
Enterprise Value | $89.50B | $16.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $220.35, up 1.05% with a bullish technical signal. The company reported strong Q1 2026 earnings of $5.96 EPS, beating estimates, and maintains robust profitability with 89.4% gross margins. Revenue growth accelerated to $23.77B in 2025, while valuation ratios remain attractive with P/E at 12.67. Recent institutional buying activity contrasts with some analyst concerns about AI competition.
Adobe presents a compelling investment case with strong fundamentals and growth trajectory, though AI disruption risks and recent stock volatility warrant caution. The consensus price target of $246.75 suggests 12% upside potential, supported by consistent earnings beats and expanding cash flows.
Neurocrine Biosciences (NBIX) trades at $174.1, showing modest daily movement with a slight decline of 0.09%. The stock exhibits strong bullish technical signals from moving averages and a consensus analyst buy rating of 86.49%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.94 surpassing the $1.22 estimate. Revenue growth is robust, climbing from $2.86B in 2025 to a projected $3.1B in 2026, supported by blockbuster products Ingrezza and Crenessity.
NBIX presents a favorable outlook with upward earnings momentum and strategic acquisitions strengthening its neuroscience portfolio. Key risks include pipeline execution challenges and competitive pressures. The consensus price target of $192.91 suggests approximately 11% upside potential from current levels, making it an attractive growth stock despite elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
